The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-positive Breast Cancer): CompassHER2 Residual Disease (RD), a Double-blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Protocol No
ALLIANCE-A011801
Principal Investigator
Lubna Chaudhary
Phase
III
Summary
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Description
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
Participating Institutions
Drexel Town Center
Froedtert Hospital
Froedtert West Bend Hospital
Froedtert Menomonee Falls Hospital
Status
OPEN TO ACCRUAL
Sub Category